在高和低凝血活性样本中的多个APTT试剂上Argatroban影响的变化
Osamu Kumano1, Masahiro Ieko2, Teruto Hashiguchi3
1Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Takamatsu, Japan.
International journal of laboratory hematology
|April 24, 2025
概括
活性部分血栓形成时间 (APTT) 试剂的反应性与阿斯巴特罗班有所不同,特别是在凝血异常的患者中. 实验室确认和患者评估对于准确的 argatroban 监测至关重要.
科学领域:
- 临床化学 临床化学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 阿格特罗班的监测通常使用激活的部分血栓形成时间 (APTT),目标范围为1.5-3.0.
- 现有的APTT试剂对阿斯拉特罗班的反应性是可变的,影响了监测的准确性.
- 在不同凝固状态下APTT试剂反应性的差异并未得到很好的定义.
研究的目的:
- 为了比较六种商业APTT试剂与 argatroban 的反应性.
- 评估阿斯拉夫罗班对正常和异常血样本中APTT比率的影响.
- 评估APTT试剂可变性的临床影响在阿斯罗班治疗中.
主要方法:
- 测试了六种具有不同激活剂和脂的商业APTT试剂.
- 正常和五个异常的血样本 (低凝血因子,高因子VIII,高因子VIIa,低纤维素素,高纤维素素) 被添加了阿斯拉夫罗班.
- 阿格特罗班度在0至2.0μg/mL之间.
主要成果:
- 在试剂之间,APTT比率有显著差异,在正常血中在2.0μg/mL argatroban时从2.4-3.2不等.
- 在具有低凝血活性 (3.3-5.2) 的样本中观察到最扩展的APTT比率范围.
- 具有高因子VIII活性的样本显示APTT比率范围 (1.5-2.2) 降低.
结论:
- 在ARGATROBAN监测中,APTT试剂之间存在显著的反应性差异.
- 异常的凝血状态会放大APTT反应性的变化,可能导致不准确的阿斯拉特罗班水平评估.
- 实验室必须验证APTT试剂的性能,并考虑患者的凝血状态,以可靠地监测阿斯拉特罗班.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
997
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
997
Anticoagulant Drugs: Low-Molecular-Weight Heparins
545
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
545
Factors Affecting Protein-Drug Binding: Drug Interactions
61
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
61
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388


